This dual-pathway development of both amyloid and tau radiotracers has enabled in vivo visualization of the two primary pathological hallmarks of AD, facilitating early diagnosis, disease progression monitoring, and therapeutic evaluation [88,89]. Here, MAPT is linked to Alzheimer disease.